Molecular Imaging

Molecular imaging (also called nuclear medicine or nuclear imaging) can image the function of cells inside the body at the molecular level. This includes the imaging modalities of positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. How does PET and SPECT imaging work? Small amounts of radioactive material (radiopharmaceuticals) injected into a patient. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT.  But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders. 

Thumbnail

Newly discovered gene sparks early amyloid changes responsible for Alzheimer’s

The findings, published June 22 in JAMA Neurology, should help identify people at the greatest risk of developing the disease.

Thumbnail

Nuclear medicine companies strike deal to produce, distribute novel PET imaging agent

Bracco subsidiary Blue Earth Diagnostics and PETNET Solutions, part of Siemens Healthineers, announced the multi-year agreement last week.

Thumbnail

NorthStar Medical Radioisotopes announces partnership to develop COVID-19 therapeutic agent

The Beloit, Wisconsin-based firm, known for producing molybdenum-99, is working with Chicago's Monopar Therapeutics on the treatment to battle severe cases of the disease.

Nuclear medicine firm SHINE vows ‘enduring commitment to normalize equality for all people’

“Black lives matter. The need to speak out against racism, racial injustice and inherent bias compels each of us as leaders in our community to act,” Founder and CEO Greg Piefer said in a recent message to employees.

Thumbnail

Radiopharmaceutical manufacturer Curium files approvals for PET imaging agent

The St. Louis-based firm submitted a stand-alone Drug Master File with the U.S. Food and Drug Administration, along with an Active Substance Master File with the European Medicines Agency, for its germanium-68 agent.

Thumbnail

Repeated negative thinking associated with amyloid and tau deposition, increased dementia risk

Engaging in such thought patterns over a long period of time could raise an individual's chance of developing the brain disease, according to a new study.

Thumbnail

FDA approves first PET agent for tau imaging

Tauvid was developed by Avid Radiopharmaceuticals, a subsidiary of Eli Lilly, and offers clinicians a new type of brain scan to use in patients being evaluated for Alzheimer's disease.

Thumbnail

FDA greenlights PET imaging agent for breast cancer

The radiopharmaceutical—Cerianna—is the first F-18 agent approved for use in patients with recurrent or metastatic breast cancer.